UROLOGIC CANCER
Clinical trials for UROLOGIC CANCER explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC CANCER trials appear
Sign up with your email to follow new studies for UROLOGIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC